Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2019 | 03-2019 | |
| Sales | 2,500 | 2,500 |
| Gross Profit | 2,500 | 2,500 |
| Operating Expenses | 5,151 | 5,358 |
| Operating Income | -2,651 | -2,858 |
| Interest Expense | 2 | 2 |
| Other Income | -200 | -323 |
| Pre-tax Income | -2,853 | -3,183 |
| Net Income Continuous | -2,853 | -3,183 |
| Net Income | $-2,853 | $-3,183 |
| EPS Basic Total Ops | -1.44 | -1.61 |
| EPS Basic Continuous Ops | -1.25 | -1.41 |
| EPS Diluted Total Ops | -1.44 | -1.61 |
| EPS Diluted Continuous Ops | -1.25 | -1.41 |
| EBITDA(a) | $-2,602 | $-2,813 |